Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CX-904

Bispecific antibody · Immune activation, directed at epidermal growth factor receptor (EGFR) and CD3 (CD3E) · developed by CytomX Therapeutics

Phase 1 Most advanced trial (none active)
CTMX Developer
1 Registered trials

What is CX-904?

CX-904 is a protease-activated bispecific antibody prodrug that binds EGFR on tumor cells and CD3 on cytotoxic T-lymphocytes once a masking peptide is cleaved by tumor-associated proteases. It redirects T cells to kill EGFR-expressing cells and is being studied in solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
epidermal growth factor receptor (EGFR), CD3 (CD3E)
Mechanism
Immune activation, directed at epidermal growth factor receptor (EGFR) and CD3 (CD3E)
Pathways
T-cell activation, CTL-mediated killing of tumor cells
Therapy area
Oncology
Developer
CytomX Therapeutics (CTMX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05387265 Phase 1 Solid Tumors Terminated CTMX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumors

Other drugs acting on EGFR / CD3E

More from CytomX Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CTMX page.

Follow CTMX, the company behind CX-904

See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTMX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.